Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

34.85 +0.78 (+2.30%)
Streaming Delayed Price Updated: 3:44 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,368,572
Open 34.54
Bid (Size) 34.85 (33)
Ask (Size) 34.86 (12)
Prev. Close 34.07
Today's Range 34.38 - 34.86
52wk Range 28.46 - 46.97
Shares Outstanding 5,385,189,617
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
Reuters 
Via Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
 
Via Benzinga

Performance

YTD
-1.23%
-1.23%
1 Month
-2.86%
-2.86%
3 Month
-0.04%
-0.04%
6 Month
+13.24%
+13.24%
1 Year
-18.64%
-18.64%

More News

Read More
3 Pharma Stocks That Could Benefit from Global Healthcare Trends
Via InvestorPlace
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?
Via The Motley Fool
Daily Stock Analysis: GSK
Via Talk Markets
How Is The Market Feeling About GSK?
Via Benzinga
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
Via Benzinga
GSK and Earvin “Magic” Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
From GSK plc
Via Business Wire
3 High Dividend Stocks With Attractive Total Return Potential
Via InvestorPlace
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
Via Investor's Business Daily
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock?
Via The Motley Fool
March 2023 Stock Considerations
Via Talk Markets
FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK's Candidate Soon After Pfizer's
Via Benzinga
3 Crucial Things to Know About Moderna Right Now
Via The Motley Fool
GSK's Relief For Few Months, First Trial Claiming Zantac Caused Cancer Pushed Into Late 2023
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields
Via Benzinga
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows
Via Benzinga
Intel and 9 Other Companies With Dividend Cuts in 2023
Via InvestorPlace
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
Via FinancialNewsMedia
My 3 Biggest Stock Market Predictions for March
Via The Motley Fool
EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue
Via Benzinga
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals
Via Benzinga
Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out
Via Benzinga
Dividend Income Update For January 2023
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.